Study demonstrates that the BNT162b2 SARS-CoV-2 XBB1.5 variant-modified vaccine significantly reduces the risk of COVID-19-related hospitalizations and ambulatory visits, outperforming previous vaccine versions in the face of evolving virus strains.
Researchers receive £2.66M to test new immunotherapeutic strategy for non-small cell lung cancer
University of Liverpool researchers have secured £2.66m Medical Research Council funding to clinically test a novel immunotherapeutic strategy for non-small cell lung cancer – one